NCT06573424View on ClinicalTrials.gov

Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC

CompletedOBSERVATIONAL
Enrollment

124

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

July 1, 2024

Study Completion Date

October 31, 2024

Conditions
Colon CancerImmunotherapy
Interventions
COMBINATION_PRODUCT

Tislelizumab+anlotinib

Patients who have been treated with anlotinib + tislelizumabline

DRUG

anlotinib

Patients who have been treated with anlotinib monotherapy

Trial Locations (1)

400042

Daping Hospital, Third Military Medical University, Chongqing

All Listed Sponsors
lead

fan li

OTHER

NCT06573424 - Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC | Biotech Hunter | Biotech Hunter